Weight-loss medications appear to slow biological aging, according to new research
Novo Nordisk and Eli Lilly find their GLP-1 weight-loss drugs may slow biological aging by two to three years, per aging-clock studies.
CLAY TRIBUNE / THE ARCHIVE
Tag: Novo Nordisk
Boehringer’s Obesity Drug Sheds Up to 13.1% of Weight in Diabetes Patients — a Disappointing Result
A medicine helped patients lose weight, yet its makers call the result a disappointment, weighed against giants already ruling that field.
Novo Agrees to Pay Up to $2.6 Billion for Hengrui Obesity Pill License
Novo Nordisk licenses a Chinese obesity pill, Roche quits a drug, and other pharma tidbits. A look at who's winning and losing in weight-loss meds.
STAT Questions Whether Trump Administration Cut Novo Nordisk a Huge Financial Win
STAT wonders if the Trump administration's MFN exemption for Lilly's GLP-1s gave Novo a hidden financial win. The answer hangs in the administration's files.
Novo Nordisk Names Five Multi-Blockbuster Targets and Promises Revenue Growth on Par With Big Pharma
Novo Nordisk promises five blockbuster drugs by 2030 and says it will sell medicines more like consumer goods.
Novartis and Novo Nordisk Lose Heart Drug Trials, Raising Doubts Over the Whole Lp(a) Field
Two drug giants lose heart trials, and the whole field of Lp(a) drugs may feel the pain.